ProKidney (NASDAQ:PROK – Get Free Report) and Rafael (NYSE:RFL – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.
Volatility & Risk
ProKidney has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Rafael has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.
Valuation & Earnings
This table compares ProKidney and Rafael”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| ProKidney | $80,000.00 | 7,896.79 | -$61.19 million | ($0.55) | -3.82 |
| Rafael | $920,000.00 | 67.81 | -$30.52 million | ($1.03) | -1.17 |
Rafael has higher revenue and earnings than ProKidney. ProKidney is trading at a lower price-to-earnings ratio than Rafael, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares ProKidney and Rafael’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| ProKidney | -9,547.45% | N/A | -18.09% |
| Rafael | -3,328.24% | -33.01% | -27.95% |
Analyst Ratings
This is a breakdown of current recommendations and price targets for ProKidney and Rafael, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| ProKidney | 2 | 1 | 3 | 0 | 2.17 |
| Rafael | 1 | 0 | 0 | 0 | 1.00 |
ProKidney currently has a consensus target price of $6.25, indicating a potential upside of 197.62%. Given ProKidney’s stronger consensus rating and higher possible upside, equities research analysts clearly believe ProKidney is more favorable than Rafael.
Institutional & Insider Ownership
51.6% of ProKidney shares are owned by institutional investors. Comparatively, 11.3% of Rafael shares are owned by institutional investors. 41.5% of ProKidney shares are owned by company insiders. Comparatively, 32.9% of Rafael shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
ProKidney beats Rafael on 10 of the 14 factors compared between the two stocks.
About ProKidney
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.
About Rafael
Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia. The company is also involved in developing Promitil, a molecule designed for the targeted delivery of mitomycin-C in a proprietary prodrug form, completed Phase 1B clinical studies; Folate-targeted Promitil (Promi-Fol) which is aimed at local treatment (intravesical) of superficial bladder cancer; and Promi-Dox, a highly potent dual drug liposome with MLP and doxorubicin targeting a potential basket of tumors. In addition, it engages in the development of surgical and procedural devices, including orthopedic arthroscopy instrumentation. Rafael Holdings, Inc. was incorporated in 2017 and is headquartered in Newark, New Jersey.
Receive News & Ratings for ProKidney Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProKidney and related companies with MarketBeat.com's FREE daily email newsletter.
